LADENBURG THALM/SH SH Begins Coverage on CeriBell (NASDAQ:CBLL)

Investment analysts at LADENBURG THALM/SH SH assumed coverage on shares of CeriBell (NASDAQ:CBLL) in a research note issued on Friday, Marketbeat.com reports. The firm set a “buy” rating and a $32.00 price target on the stock. LADENBURG THALM/SH SH’s price objective suggests a potential upside of 73.54% from the company’s previous close.

Several other research firms have also issued reports on CBLL. Canaccord Genuity Group restated a “buy” rating and issued a $33.00 price target on shares of CeriBell in a research report on Wednesday, February 26th. TD Cowen lifted their target price on CeriBell from $31.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, CeriBell presently has a consensus rating of “Buy” and an average price target of $32.50.

CeriBell Price Performance

CeriBell stock opened at $18.44 on Friday. The stock’s fifty day moving average price is $21.95. CeriBell has a fifty-two week low of $17.67 and a fifty-two week high of $32.75.

CeriBell (NASDAQ:CBLL) last announced its earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.08). The company had revenue of $18.53 million during the quarter, compared to analysts’ expectations of $17.55 million. Equities analysts forecast that CeriBell will post -2.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CeriBell

A number of institutional investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers bought a new position in shares of CeriBell during the 4th quarter worth approximately $320,000. PNC Financial Services Group Inc. bought a new position in shares of CeriBell during the fourth quarter valued at $47,000. Emerald Advisers LLC acquired a new stake in shares of CeriBell in the 4th quarter valued at $3,126,000. Bank of New York Mellon Corp bought a new stake in shares of CeriBell in the 4th quarter worth about $628,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in shares of CeriBell during the 4th quarter worth about $2,500,000.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.